Pharma News
30 Nov 2025 to 06 Dec 2025
Dec 6, 2025
Rajasthan's FSDC Confiscates ₹3.73 Crore in Counterfeit Medications During Unlicensed Operation
The Food Safety and Drug Control Rajasthan (FSDC) conducted a raid on a wholesale firm in Jaipur, seizing counterfeit and substandard medicines worth ₹3.73 crore. This operation highlights the ongoing efforts to combat the illegal trade of fake pharmaceuticals in the region.
Dec 6, 2025
India's Pharmaceutical and Medical Technology Industries Move Towards Self-Sufficiency
India's government announced key initiatives to enhance self-reliance in the pharma and MedTech sectors, focusing on innovation, domestic manufacturing, and export growth. These measures aim to strengthen infrastructure and drive advancements in the industry, marking a significant step towards boosting India's position in global markets.
Dec 6, 2025
Mezzion Pharmaceuticals receives notice of allowance from the USPTO for its exclusivity on udenafil in ...
Mezzion Pharmaceuticals Inc announced a Notice of Allowance from the USPTO for a key patent covering the use of JURVIGO (udenafil) to improve exercise capacity in Fontan patients. This patent could extend US protection into the early 2040s, pending FDA approval. JURVIGO aims to be the first treatment for individuals with single ventricle congenital heart disease.
Dec 6, 2025
UPSC Highlights: Modi and Putin outline future plans, Semaglutide patent litigation, and fighter pilot ejection test.
Dr. Reddy's Laboratories (DRL) has been allowed by the Delhi High Court to continue manufacturing and exporting its semaglutide drug, despite a patent infringement suit from Novo Nordisk. The court found DRL's challenge to Novo Nordisk's patent valid, citing issues of "evergreening." This ruling supports the growth of generic competition in the lucrative diabetes and obesity treatment market.
Dec 6, 2025
Novo Nordisk Confronts Two Major Issues: Fake Medications and Patent Challenges | NewsCase
Novo Nordisk faces challenges as U.S. regulators seized counterfeit Ozempic (semaglutide-patent-expiration" style="color: #F36C42; font-weight:600";>Semaglutide) units, while an Indian court ruling allows Dr. Reddy’s Laboratories to produce the drug for export, intensifying competition. Additionally, recent Phase 3 trials for an oral semaglutide formulation for Alzheimer’s disease failed, impacting the company's neurological portfolio. Investors are urged to assess the implications for Novo Nordisk's market position.
Dec 6, 2025
Abbott urges distributors to purchase exclusively from approved suppliers, according to DrugsControl Media Services.
Abbott Healthcare has urged stockists and distributors to purchase medicines exclusively from authorised suppliers following a Puducherry government alert about the seizure of counterfeit drugs. The company emphasizes the importance of sourcing genuine products to ensure safety and compliance in the pharmaceutical market.
Dec 6, 2025
Market for Generic Oncology Medications: Increasing Access to Cost-Effective Cancer Treatment - openPR.com
The Generic Oncology Drug Market is projected to grow from USD 26.9 billion in 2023 to USD 44.1 billion by 2032, driven by rising cancer incidence, patent expirations, and demand for affordable treatments. Key players include Teva Pharmaceuticals, Sandoz, and Sun Pharma. This market is crucial for improving access to cancer care globally, especially in low-income regions.
Dec 6, 2025
Reasons Behind Delhi HC's Dismissal of Semaglutide Patent Case | Detailed Analysis - The Indian Express
The Delhi High Court has denied Novo Nordisk's request for an interim injunction against Dr Reddy’s Laboratories (DRL), allowing DRL to continue manufacturing and exporting its semaglutide product. The court deemed DRL's challenge to Novo Nordisk's patent as prima facie valid, marking a significant victory for generic drug makers in the competitive GLP-1 market.
Dec 5, 2025
Genet Pharma Secures U.S. Patent for Lyophilized Nellonemdaz Injectable - Asia Economy
Genet Pharma announced on December 5 that it has received a patent from the USPTO for the lyophilized powder injectable formulation of its neuroprotective agent, Nellonemdaz, aimed at treating stroke. This patent enhances the drug's stability and supports its global commercialization strategy, following two previous patents. Nellonemdaz has shown significant efficacy in clinical trials, positioning it as a potential breakthrough in stroke treatment.
Dec 5, 2025
Merck faces a challenge with its new Keytruda formulation in Germany - STAT News
Merck faces a setback as a German court issued a preliminary injunction halting the distribution of its new subcutaneous formulation of Keytruda due to a patent infringement dispute with Halozyme Therapeutics. The Munich Regional Court ruled that Merck's formulation infringes on Halozyme's patent, but patients can still access the existing intravenous version of Keytruda.
Dec 5, 2025
Mandatory Licensing: A Tool for Reconciling Patent Rights with Essential Needs
Compulsory licensing (CL) is a controversial legal mechanism allowing governments to permit third parties to manufacture patented drugs without the owner's consent, aimed at making life-saving medications affordable. The 2012 Indian case of Natco Pharma, which produced Sorafenib Tosylate at a significantly lower price than Bayer, exemplifies CL's potential to enhance access to essential treatments.
Dec 5, 2025
Nationwide Enforcement Efforts Increase: Confiscation of Codeine Cough Syrups and Opioid Medications on the Rise...
India's crackdown on illicit narcotics intensifies, with enforcement agencies seizing thousands of banned Codeine cough syrup bottles, Pregabalin Capsules, and Tapentadol Tablets. The operations have led to multiple arrests as authorities continue their war against fake and abused drugs.
Dec 5, 2025
Will Galafold Sustain Amicus' Revenue Growth Through 2026? - TradingView
Amicus Therapeutics (FOLD) reported strong sales for its lead product, Galafold (migalastat), generating $371.5 million in the first nine months of 2025, a 12% increase year-over-year. The drug, approved for Fabry disease, faces competition from Sanofi's Fabrazyme and Takeda's Replagal. Amicus also saw success with Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), generating $77.5 million.
Dec 5, 2025
Aspire Biopharma Shares Business Update for Q3 2025 - BioSpace
Aspire Biopharma Holdings, Inc. has made significant strides in Q3 2025, including submitting a Pre-IND request for a fast-acting sublingual aspirin for acute myocardial infarction to the FDA. The company also expanded its team, filed a patent application for its sublingual delivery technology, and launched its BUZZ BOMB™ caffeine product, enhancing production capacity. Interim CEO Kraig Higginson highlighted upcoming milestones, including a targeted NDA submission in H1 2026.
Dec 4, 2025
AstraZeneca's Stock Falls 0.7% Due to Concerns Over Patent Expiration, Yet Robust Pipeline Supports Long-Term Outlook
AstraZeneca PLC shares fell 0.7% to 13,546p amid concerns over impending patent expirations for drugs like Symbicort and Seroquel XR, potentially costing the company £3 billion by 2028. Despite strong Q3 results and a robust oncology portfolio, including Enhertu and Imfinzi, the stock's decline reflects broader market anxieties. CEO Pascal Soriot emphasizes innovation as the company's future focus.
Dec 4, 2025
The widely anticipated obesity medication "Munzaro" has successfully cleared its initial health assessment.
Lilly Korea's obesity treatment "Munzaro," containing the active ingredient tirzepatide, has passed the initial evaluation for health insurance coverage as an adjunct therapy for type 2 diabetes. The final decision will follow price negotiations with the National Health Insurance Corporation. Munzaro has shown significant weight loss results, leading to high demand since its launch in August.
Dec 4, 2025
Hims reveals it has purchased the Canadian telehealth company Livewell - Sherwood News
Hims & Hers has announced its acquisition of Canadian telehealth firm Livewell, marking its entry into the Canadian market. This move coincides with the upcoming patent expiry of semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy. Hims also recently acquired YourBio, a blood sample collection device, in another all-cash deal.
Dec 4, 2025
Assessing the Strength of AbbVie's Immunology Division Following Humira's Loss of Exclusivity - The Globe and Mail
AbbVie (ABBV) is experiencing robust growth in the immunology sector, driven by its blockbuster drugs Skyrizi and Rinvoq, which have seen a 53% sales increase to $18.5 billion this year. Despite losing exclusivity for Humira, AbbVie anticipates combined sales of Skyrizi and Rinvoq to exceed $31 billion by 2027, bolstered by new indications and strong market share gains.
Dec 4, 2025
Combination of Pliant's Cancer Medication with Merck's Keytruda Enhances Treatment Responses in ...
Pliant Therapeutics, Inc. (NASDAQ:PLRX) reported promising interim results from its Phase 1 trial of PLN-101095, combined with Merck & Co. Inc.’s (NYSE:MRK) Keytruda, in patients with advanced solid tumors. The treatment showed antitumor activity, with a confirmed complete response and three partial responses. Despite these results, PLRX shares fell 20.45%, trading near a 52-week low.
Dec 4, 2025
Avecho Obtains Patent Approvals in the US and Europe for CBD Soft-Gel Capsules
Avecho Biotechnology Limited has received patent allowances in the US and Europe for its CBD soft-gel capsule formulation, currently in Phase III trials for insomnia. These patents, expected by FY26, will protect the formulation until at least 2040, enhancing Avecho's intellectual property and market position in cannabinoid technology. The ongoing trial aims to support registration for insomnia treatment.
Dec 4, 2025
Delhi High Court permits Dr. Reddy's to manufacture and export weight-loss medication - The Indian Express
The Delhi High Court denied Novo Nordisk's request for an interim injunction, allowing Dr Reddy’s Laboratories to manufacture and export its version of the GLP-1 drug semaglutide. The court found that Novo Nordisk's double patenting strategy, aimed at extending its monopoly, was not valid. Novo Nordisk's species-specific patent for semaglutide expires in March 2026.
Dec 4, 2025
Global: WHO supports GLP-1 therapies in the fight against obesity crisis - New Vision
The WHO has issued guidelines endorsing GLP-1 agonists, including Ozempic and Mounjaro, as key tools in treating obesity, which affects over one billion globally. While effective, the WHO cautions these drugs are not a "magic bullet" and should be combined with lifestyle changes. Concerns about access and affordability in poorer nations persist, as obesity-related health costs could reach $3 trillion by 2030.
Dec 4, 2025
Delhi High Court Denies Novo Nordisk's Request for Injunction, Permitting Dr. Reddy's to Produce ...
The Delhi High Court denied Novo Nordisk's request for an interim injunction against Dr. Reddy's Laboratories and OneSource Specialty Pharma regarding semaglutide, used in Ozempic and Wegovy. The court found Novo failed to prove patent infringement, allowing the Indian companies to manufacture and export the drug while prohibiting sales in India until Novo's patent expires in 2026.
Dec 4, 2025
Delhi High Court Approves Dr. Reddy's Production of Semaglutide for Export Purposes
The Delhi High Court has allowed Dr. Reddy’s Laboratories Limited to manufacture and export Semaglutide, a diabetes treatment drug, to countries where Novo Nordisk AS does not hold a patent. The court found that Novo Nordisk failed to establish a prima facie case for an interim injunction, as it does not manufacture the drug in India.
Dec 4, 2025
Maharashtra government approves funding of Rs 9.59 crore for the purchase of devices to detect counterfeit medications.
The Maharashtra government has approved Rs 9.59 crore for the acquisition of eight counterfeit drug detection devices. This initiative aims to enhance the identification of fake and substandard medicines in public hospitals, bolstering the state's efforts to ensure drug safety and integrity.
Dec 4, 2025
Galmed Reveals Approval of New Use Patents for the Aramchol Combination with ...
Galmed Pharmaceuticals Ltd. announced the grant of a new Use Patent in South Korea for its lead compound, Aramchol, covering its combination therapy with Madrigal Pharmaceuticals' Rezdiffra for treating non-alcoholic steatohepatitis (NASH). This patent extends Aramchol's protection until July 2042, reinforcing its position in the growing field of combination therapies for liver diseases.
Dec 4, 2025
Aspire Biopharma Releases Business Update for the Third Quarter of 2025 - PharmiWeb.com
Aspire Biopharma Holdings, Inc. has made significant strides in Q3 2025, including submitting a Pre-IND request for its fast-acting sublingual aspirin for acute myocardial infarction to the FDA, which responded positively. The company also launched its BUZZ BOMB™ caffeine product and expanded its scientific team. Aspire aims for a New Drug Application submission in H1 2026.
Dec 4, 2025
Halozyme Secures Initial Injunction Against Merck's Keytruda SC in Germany
Halozyme Therapeutics has secured a preliminary injunction from a German court, preventing Merck from distributing Keytruda SC in Germany due to patent infringement of Halozyme's MDASE™ technology. The court found imminent infringement related to European Patent No. 2 797 622. Patients can still access the IV version of Keytruda, unaffected by the injunction.
Dec 4, 2025
Action Taken Against Drug Trafficking Operations: Significant Seizures of Codeine Cough Syrup
In a nationwide crackdown on narcotic drug rackets, Indian enforcement agencies seized significant quantities of Codeine cough syrup, Pregabalin capsules, and Tapentadol. The operation led to multiple arrests and ongoing investigations into related bank accounts, highlighting the government's commitment to combat illegal drug trade.
Dec 4, 2025
Complete Reversal by Federal Authorities: Patent Term Extension Denied for Drug Formulation
The Full Federal Court's decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd restricts patent term extensions (PTE) in Australia to active pharmaceutical ingredients (APIs) only, excluding formulation patents. This ruling emphasizes the need for strategic patent filings focused on APIs, as formulation claims are no longer eligible for PTE, aligning with legislative intent to compensate for regulatory delays on new substances.
Dec 4, 2025
Novo Nordisk is preparing to introduce its diabetes medication Ozempic in India this month - Business Standard
Novo Nordisk is set to launch its diabetes drug Ozempic in India this month, aiming to capture a share of the growing weight-loss market. With rising diabetes and obesity rates in India, Ozempic, a semaglutide-based injectable, will complement Novo's existing offerings. The company is focused on competitive pricing as it faces competition from Eli Lilly's Mounjaro.
Dec 4, 2025
Sources indicate that Novo Nordisk plans to launch Ozempic in India this December.
Novo Nordisk is set to launch its diabetes drug Ozempic in India this December, addressing the country's rising type 2 diabetes and obesity rates. Approved in the U.S. since 2017, Ozempic has seen off-label use for weight loss. The launch comes amid competition from Eli Lilly’s Mounjaro and local generics from companies like Sun Pharma and Cipla.
Dec 4, 2025
Major Pharmaceutical Products Approaching Patent Expiration: Industry Challenges - openPR.com
The global market for blockbuster drugs facing patent expirations, including Humira, Revlimid, and Keytruda, is set to grow from USD 45.3 billion in 2023 to USD 82.1 billion by 2034, at a CAGR of 6.3%. The rise of generics and biosimilars presents both challenges and opportunities for the pharmaceutical industry as it adapts to increased competition.
Dec 4, 2025
Study finds weight-loss medication too costly for public patients - RTE
A study by the National Centre for Health Economics found that the weight-loss drug Mounjaro, produced by Eli Lilly, is not cost-effective for public patients at its current price, which ranges from €5,526 to €6,214 annually. A 73% price reduction is needed for it to be considered value for money. The drug's high demand and potential budget impact raise concerns about affordability and access.
Dec 3, 2025
Ensysce Biosciences Reveals Expanded Patent Coverage for Innovative MPAR(R) Technology
Ensysce Biosciences has received a Notice of Allowance for a new U.S. patent extending protection for its MPAR® (Multi-Pill Abuse Resistance) technology through 2042. This patent enhances Ensysce's intellectual property for overdose protection, particularly for its PF614-MPAR product, which aims to reduce opioid abuse and overdose risks. The technology is also being applied to other drug classes.
Dec 3, 2025
The U.S. biopharmaceutical firm Merck intends to generate $8 billion by issuing bonds.
Merck & Co. plans to raise $8 billion through bond sales to finance its $9.2 billion acquisition of Cidara Therapeutics Inc., aimed at enhancing its antiviral drug portfolio. The bond issuance will consist of 8 tranches with maturities from three to 40 years. The deal is expected to close in Q1 2026, pending regulatory approval.
Dec 3, 2025
A weekly injection similar to Ozempic is currently being trialed on the heaviest cats and dogs in the United States.
Akston has launched a clinical trial at Cornell University to test its GLP-1 injection, AKS-562c, for treating obesity in cats. With over 60% of US cats classified as overweight, this once-weekly therapy aims to address a significant health issue. The trial seeks to enroll 70 to 140 cats, offering a potential breakthrough in veterinary medicine.
Dec 3, 2025
Focused enforcement on the supply side of the regulated drug market
A study by Adam Soliman in the American Economic Journal reveals that targeting rogue doctors can reduce opioid prescriptions by 10% without shifting supply to neighboring areas. However, while overall opioid mortality decreased, heroin overdoses surged by 50%, indicating a dangerous substitution effect. The findings suggest a need for balanced supply-side and demand-side interventions in combating the opioid epidemic.
Dec 3, 2025
Eli Lilly Reduces Zepbound Prices to Increase Accessibility for Obesity Therapy
Eli Lilly has reduced cash prices for its obesity drug Zepbound, offering the 2.5 mg dose at $299, down from $349, to improve access amid rising demand. The price cuts aim to assist uninsured and under-insured patients. Zepbound, based on tirzepatide, is a leading weight-loss therapy, contributing to Lilly's market value exceeding $1 trillion this year.
Dec 3, 2025
Eli Lilly Escalates Competition in the Weight-Loss Medication Sector - Ad-hoc-news.de
Eli Lilly has reduced the out-of-pocket cost for its weight-loss drug, Zepbound, to $299 per month, down from $349, in response to competition from Novo Nordisk's Wegovy and Ozempic. This strategic move aims to capture the self-pay market ahead of Medicare expansions. Analysts remain optimistic, with price targets set at $1,100 and $1,300.
Dec 3, 2025
Eli Lilly Reduces Zepbound Costs in Response to Competition in Obesity Medication Market - Evrim Ağacı
Eli Lilly has reduced prices for its weight-loss drug Zepbound, now costing $299 per month for cash-pay customers, in response to competition from Novo Nordisk and political pressure for affordable obesity treatments. The price cuts aim to improve access for millions of Americans, with further reductions planned for 2026 as part of a White House deal.
Dec 3, 2025
Australia's Regulatory Authority Raises Concerns About Potential Mental Health Issues Associated with Widely Used Weight-Loss Medications
Australia's Therapeutic Goods Administration has issued a safety warning regarding potential mental health risks, including suicidal thoughts, linked to GLP-1-based weight-loss drugs like Ozempic (semaglutide) and Mounjaro (tirzepatide). Despite rising use in India, no similar alert has been issued. The FDA is also monitoring the situation, noting a small risk cannot be ruled out.
Dec 3, 2025
Savara and PARI Awarded a European Patent for Their Drug-Device Combination ... - BioSpace
Savara Inc. announced that the European Patent Office has issued a patent for its investigational therapy, MOLBREEVI, in combination with PARI's eFlow® Nebulizer System. This patent, valid until March 2043, enhances the protection of MOLBREEVI for treating autoimmune pulmonary alveolar proteinosis (PAP) in Europe. The company plans to resubmit its BLA in the U.S. in December and submit its MAA in Europe and the U.K. in early 2026.
Dec 3, 2025
High Court allows Dr. Reddy's to produce Novo's weight loss medication - The Times of India
The Delhi High Court has permitted Dr Reddy’s Laboratories to manufacture and export semaglutide, challenging Novo Nordisk's patent, which is deemed prima facie invalid. This ruling could enhance competition in India's Rs 850 crore obesity market, especially with the patent expiration approaching in March. Novo Nordisk's Wegovy faces competition from Eli Lilly’s Mounjaro as it reduces prices and partners with Emcure Pharma.
Dec 3, 2025
ED Takes Action Against Pharmaceutical Corruption in Himachal: Seizes Assets Worth ₹2.58 Crore from ADC
The Enforcement Directorate (ED) has provisionally attached assets worth ₹2.58 crore belonging to Nishant Sareen, a key figure in Himachal Pradesh's pharmaceutical regulatory system, amid a multi-crore bribery scandal. This action is part of a broader investigation under the Prevention of Money Laundering Act (PMLA) 2002, with total seized assets exceeding ₹6 crore.
Dec 3, 2025
Teva vs. Kennedy: Analyzing Patent Exclusivity and Pricing Regulations | Knobbe Martens - JDSupra
On November 20, 2025, the DC District Court ruled against Teva Pharmaceuticals USA, Inc. in its challenge to the Medicare Drug Price Negotiation Program under the Inflation Reduction Act of 2022. The court affirmed that patent rights do not guarantee pricing freedom, supporting the government's ability to negotiate fair prices for patented drugs. This ruling aligns with similar decisions against other drug manufacturers.
Dec 3, 2025
Nationwide Operation Targets Drug Trafficking Networks: Law Enforcement Confiscates Cough Syrups and Tablets...
Indian authorities have launched a nationwide crackdown on narcotic drug syndicates, seizing codeine-laced cough syrups, pregabalin capsules, and tapentadol tablets worth crores. The operations have led to the arrest of dozens and the freezing of assets across multiple states, marking a significant effort to combat the illegal drug trade.
Dec 3, 2025
Delhi High Court permits Dr. Reddy's to produce and export Semaglutide to markets without patent protections.
Justice Manmeet Pritam Singh Arora ruled in favor of Dr. Reddy's, allowing the company to manufacture and export a drug despite a patent challenge from Novo Nordisk. The court found Dr. Reddy's arguments on prior claiming and obviousness credible, permitting production for non-patented territories as Novo Nordisk only imports the drug to India.
Dec 3, 2025
How mass spectrometry guarantees the safety and effectiveness of GLP-1 medications
Therapeutic peptides, particularly GLP-1 receptor agonists like semaglutide and liraglutide, are transforming chronic disease treatment. With over 100 peptide drugs approved, their complexity necessitates advanced analytical methods like high-resolution accurate mass spectrometry (HRAM-MS) for quality assurance. As patents expire, biosimilar developers rely on these technologies to ensure safety and efficacy in peptide therapeutics, marking a new era in medicine.
Dec 3, 2025
Wockhardt's New Antibiotic Zaynich Receives NDA Approval from US FDA | - Chemical Industry Digest
Wockhardt announced that the US FDA has accepted its New Drug Application for Zaynich, a first-in-class antibiotic aimed at combating antimicrobial resistance. This marks a historic milestone as it is the first NDA for a New Chemical Entity from an Indian company. Zaynich has received 'Fast Track' designation and shows promise against resistant pathogens, with a significant market opportunity estimated at ₹17,000 crore in India and $7 billion in the US and Europe.
Dec 3, 2025
Ashurst: Formulations ineligible for extensions of patent terms in Australia.
The Full Court of Australia ruled that only patents claiming active ingredients are eligible for patent term extensions (PTEs), impacting Otsuka Pharmaceutical's aripiprazole patent. This decision may lead to challenges against previously granted "zombie PTEs." Sun Pharma, represented by Ashurst, successfully contested the PTE, prompting Otsuka to consider an appeal to the High Court.
Dec 3, 2025
Assessing the Patent Eligibility of Biotech Innovations According to Turkish Legislation - Mondaq
Turkey's patent law on biotechnological inventions emphasizes the need for novelty, inventive step, and industrial applicability, while also addressing ethical concerns. Key exclusions include human cloning and the commercialization of human genetic materials. The balance between innovation and public interest remains crucial, aligning Turkey's regulations with international standards like the EPC and TRIPS.
Dec 3, 2025
Exploring the Framework and Case Studies of China's Pharmaceutical Patent Linkage System
China's Patent Linkage System, effective since June 2021, links drug patent status to marketing authorization processes, aiming to resolve patent disputes before generic drug approvals. The system, governed by Article 76 of the Patent Law, has seen 183 administrative adjudications and 50 civil judgments, balancing timely generic entry with original drug patent protection.
Dec 3, 2025
Pharmexcil Reports Increase in Pharmaceutical Exports as Major Medications Expire on Patents - Chemical Industry Digest
Pharmaceutical exports from India are projected to grow significantly, driven by over $250 billion in innovator drugs going off patent by 2030, according to Pharmexcil Vice-Chairman Bhavin Mehta. With domestic demand rising and easing concerns in the US market, India exported $30.47 billion in pharmaceuticals in 2024-25, primarily generics. Enhanced quality assurance for cough syrups is also being implemented.
Dec 3, 2025
Kiora Pharma has been granted a US patent for new formulations related to the KIO-100 product line.
Kiora Pharmaceuticals, Inc. announced the issuance of a new patent (US-12,472,263) for novel formulations of its KIO-100 compounds, enhancing delivery options for KIO-104, a DHODH inhibitor. Currently, KIO-104 is undergoing a phase 2 trial (KLARITY) for retinal inflammation, aiming to provide alternatives to steroids in treating conditions like diabetic macular edema.
Dec 3, 2025
High Court permits Dr. Reddy's and OneSource Pharma to ship semaglutide to select countries - Informist
The Delhi High Court has allowed Dr. Reddy's Laboratories and OneSource Speciality Pharma to manufacture and export their version of the diabetes drug 'semaglutide', despite Novo Nordisk's patent claims. However, they cannot sell it in India until March 2026. Novo Nordisk's patent on 'semaglutide' is challenged, with the primary patent expiring in September 2024.
Dec 2, 2025
Pfizer's Cancer Medications Show Growth Despite Market Competition - Finviz
Pfizer (PFE) has strengthened its oncology portfolio with the acquisition of Seagen, adding four antibody-drug conjugates (ADCs) that contributed significantly to its revenues. Oncology sales grew 7% year-to-date, driven by drugs like Xtandi and Padcev. Despite a 4.7% stock decline this year, Pfizer's valuation remains attractive, with earnings estimates rising for 2025 and 2026.
Dec 2, 2025
Biosimilars Update: Increased Approvals Following Policy Adjustments
In November 2025, the FDA approved multiple denosumab biosimilars, enhancing competition in osteoporosis and cancer therapies. Notably, Poherdy, the first interchangeable biosimilar for Perjeta, was also approved. Discussions on regulatory reforms and market access highlighted the need for streamlined policies to boost biosimilar uptake, with potential savings of over $38.6 million projected for denosumab adoption.
Dec 2, 2025
Odisha's Counterfeit Medication Issue Escalates: 168 Seized Over Four Years, Valued at Rs 2.5 Lakh
Odisha's Health Minister Dr. Mukesh Mahaling reported a significant rise in counterfeit medicines, with 168 fake drugs seized over four years, valued at Rs 2.5 lakh. The alarming situation poses serious risks to public health, prompting urgent discussions in the state assembly.
Dec 2, 2025
March-in provisions of the Bayh-Dole Act pose a threat to the pharmaceutical development industry in the United States.
A recent rebuttal from the Bayh–Dole Coalition's executive director challenges claims that the Bayh–Dole Act allows the government to intervene in high-priced drugs with government-funded patents. The response emphasizes that both the Biden and Obama administrations found no basis for such actions and highlights that industry funding for FDA-approved therapies far exceeds government contributions.
Dec 2, 2025
Research Underway on GLP-1 Medications as Possible Obesity Treatment for Cats and Other Animals
Researchers are exploring the use of GLP-1 receptor agonists, such as Ozempic and Wegovy, as potential treatments for obesity in pets, particularly cats. This study aims to address the rising concern of pet obesity linked to health issues. Ongoing trials will assess the safety and efficacy of these drugs in veterinary medicine before any potential approval.
Dec 2, 2025
Xeris Receives Notice of Allowance from the U.S. Patent and Trademark Office for XP-8121
Xeris Biopharma Holdings, Inc. announced that the USPTO has issued a Notice of Allowance for its subsidiary's patent application covering XP-8121, a novel formulation of levothyroxine sodium for hypothyroidism. This patent strengthens Xeris' intellectual property protection and highlights the potential of XP-8121 as a once-weekly subcutaneous injection using the XeriSol® technology platform.
Dec 2, 2025
A recent survey reveals that 80% of Americans are in favor of patent reform aimed at reducing medication costs.
A national survey reveals 80% of Americans support patent reform to tackle rising prescription drug costs, with bipartisan consensus on the need for change. Conducted by I-MAK, the survey highlights that many Americans struggle to afford medications, attributing high prices to pharmaceutical company greed. Key reforms include easing access to generics and allowing Medicare to negotiate prices.
Dec 2, 2025
Telangana DCA introduces ODLS website to enable public verification of pharmacy licenses.
The Telangana Drugs Control Administration (DCA) has launched the Online Drug License System (ODLS) website, enabling citizens to verify the legitimacy of medical shop licenses. This initiative aims to enhance public health safety by ensuring transparency in the operation of pharmacies across the state.
Dec 2, 2025
Could groundbreaking obesity medications transform the approach to addiction therapy? - Nature
Recent research suggests that GLP-1 drugs, particularly semaglutide (Ozempic, Wegovy), may help reduce addiction to substances like alcohol and opioids. Studies indicate these medications can alter brain pathways related to craving and reward. Ongoing clinical trials are exploring their efficacy in treating substance use disorders, potentially revolutionizing addiction medicine.
Dec 2, 2025
Broadened Medicare Benefits May Provide Access to GLP-1 Medications for Millions - Medscape
The federal government announced plans to lower prices for obesity drugs, including Eli Lilly's Zepbound and Novo Nordisk's Wegovy, expanding access for Medicare enrollees. Patients could pay no more than $50 monthly, benefiting around 7 million individuals. However, concerns remain about eligibility, coverage details, and potential prior authorization hurdles for primary care providers.
Dec 2, 2025
Novo and J&J's unsuccessful Alzheimer's trials offer important insights for the struggling industry | PharmaVoice
Recent setbacks in Alzheimer's research have emerged as Novo Nordisk's semaglutide failed to outperform a placebo in late-stage trials, while Johnson & Johnson discontinued its mid-stage study of the anti-tau antibody posdinemab. Experts suggest these failures may enhance understanding of the disease, paving the way for future therapies. J&J will now focus on its immunotherapy candidate JNJ-2056.
Dec 2, 2025
Could Weight Loss Medications Transform Overweight Cats into Slimmer Ozempets? - Gesundheit - DerStandard
GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro, may soon be used for pets as obesity and diabetes rates rise among cats and dogs in the U.S. With approximately 60% of pets affected, the potential market for these weight loss and diabetes medications is significant as new formulations become available.
Dec 2, 2025
WHO Approves GLP-1 Medications Worldwide: What You Need to Know About Their Impact on Weight Management...
The WHO has issued its first global guidelines endorsing GLP-1 receptor agonists, including semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), for obesity treatment. The recommendations emphasize a comprehensive approach combining medication with lifestyle changes. However, concerns over cost, equity, and safety persist, highlighting the need for global cooperation to ensure access and monitor long-term effects.
Dec 2, 2025
Puducherry's Drug Control Department Notifies DCGI About 34 Potential Counterfeit Cases
The Puducherry Drugs Control Department has alerted the DCGI about 34 suspected counterfeit and spurious medicines found in the local market during November 2025. This significant discovery raises concerns over drug safety in the Union Territory.
Dec 2, 2025
Delhi High Court Permits Dr. Reddy's to Export Semaglutide, Prohibits Domestic Sales Until 2026
A recent ruling allows the uninterrupted production of semaglutide for export, while prohibiting any domestic commercial activities related to the drug until the patent expires in 2026.
Dec 2, 2025
Dr. Reddy's receives approval from Delhi High Court to export semaglutide to markets without patent restrictions - Mint
Dr Reddy’s has contested a patent under Section 64 of the Patents Act, alleging an "evergreening" attempt to prolong monopoly protection. The company claims it received regulatory approval in December 2024 to manufacture semaglutide for export, citing India’s Bolar exemption (Section 107A) that allows exporting patented drugs to countries with expired patents.
Dec 2, 2025
Daiichi secures victory in appeal regarding $42 million US ruling in Enhertu patent dispute - TradingView
A U.S. appeals court has overturned a $42 million jury verdict against Daiichi Sankyo and AstraZeneca regarding their cancer drug Enhertu, ruling that Seagen's patent was invalid. Pfizer expressed disappointment with the decision, as Seagen, acquired by Pfizer for $43 billion in 2023, had claimed Enhertu infringed on its patent rights.
Dec 1, 2025
WHO Calls for Broader Availability of Obesity Treatments in Response to Escalating Crisis
The WHO warns of a looming health crisis as global obesity rates rise, highlighting that fewer than 10% of individuals who could benefit from obesity medications like Wegovy can access them. The organization has added GLP-1 medications to its essential medicines list and urges governments and pharmaceutical companies to improve accessibility, especially as obesity-related health issues escalate worldwide.
Dec 1, 2025
Market for Major Drugs Facing Patent Expirations is Anticipated to Grow
The Blockbuster Drugs on Patent Cliffs Market is projected to reach USD 148 billion by 2034, driven by over USD 258 billion in branded drugs losing patent protection between 2024 and 2030. Key drugs affected include Keytruda (Merck), Opdivo (BMS), and Eliquis (BMS/Pfizer). The market is expected to grow at a 7.1% CAGR, presenting significant opportunities for generics and biosimilars.
Dec 1, 2025
Eli Lilly reduces the cash prices for Zepbound weight loss medication vials on its direct-to-consumer platform.
Eli Lilly has reduced the cash price of its weight loss drug Zepbound on its LillyDirect platform, with starting doses now available for $299 per month, down from $349. This move follows recent price cuts by rival Novo Nordisk for its drugs Wegovy and Ozempic. The changes aim to improve access for patients amid ongoing efforts to make obesity treatments more affordable.
Dec 1, 2025
WHO supports GLP-1 therapies in the fight against the obesity crisis - BNN Bloomberg
The World Health Organization (WHO) has issued new guidelines endorsing GLP-1 agonists, including Ozempic and Mounjaro, as key tools in treating obesity, which affects over one billion people globally. While these drugs can aid in weight loss, WHO emphasizes they are not a standalone solution and must be combined with lifestyle changes and broader health policies to combat the obesity epidemic effectively.
Dec 1, 2025
Lilly Reduces Zepbound Costs Once More for Direct-to-Consumer Purchases - BioSpace
Eli Lilly has reduced the price of its obesity drug Zepbound, with the lowest dose now costing $299, down from $349. The 5-mg dose is reduced to $399, while other doses drop to $449. This follows Novo Nordisk's announcement of a self-pay option for its GLP-1 drugs, Wegovy and Ozempic, priced at $199.
Dec 1, 2025
Eli Lilly reduces the cost of Zepbound vials on its consumer-facing platform - Sherwood News
Eli Lilly has reduced the cash-pay price of its obesity drug Zepbound to $299-$449 per month, amid a pricing war with Novo Nordisk, which recently cut the price of its weight-loss shot Wegovy. Both companies aim to capture market share against competitors like Hims & Hers, while also agreeing to lower government prices through the upcoming TrumpRx platform.
Dec 1, 2025
Comprehensive Analysis of Biologics by Morgan Lewis
The Blockbuster Biologics Review, produced by intellectual property lawyers, provides quarterly updates on inter partes review (IPR) challenges and patent litigation related to blockbuster biologic drugs. The report covers the current status of IPR challenges, institution and invalidation rates, and ongoing patent litigations, with regular updates planned for the future.
Dec 1, 2025
Fake weight loss medications present significant risks - Digital Journal
A recent ZAVA survey reveals that over 21% of UK weight-loss medication users obtained drugs without a prescription, with many purchasing from online marketplaces like eBay. Counterfeit semaglutide, linked to a death, poses serious risks. Social media influences buying habits, with young adults most likely to seek unregulated options. Authorities warn of the dangers of counterfeit weight-loss drugs.
Dec 1, 2025
WHO advises the use of weight loss medications and healthy living practices to address obesity.
The World Health Organization (WHO) has issued its first guidance on using blockbuster weight loss drugs, including Wegovy and Mounjaro, to treat obesity. The recommendations emphasize combining these GLP-1 receptor agonists with exercise, diet, and counseling for effective long-term management. The guidance highlights the need for equitable access and integrated care to combat the global obesity epidemic.
Dec 1, 2025
Negotiations between Canada’s public drug programs and Novo Nordisk regarding coverage for Wegovy have concluded - The Globe and Mail.
Negotiations between Canada’s pan-Canadian Pharmaceutical Alliance and Novo Nordisk over the weight-loss drug Wegovy have ended without a deal due to pricing disagreements. Wegovy, containing semaglutide, is priced higher than Ozempic, which is already covered by public health plans. Patient advocates express disappointment over the lack of access to effective treatments for Canadians.
Dec 1, 2025
Roche: Although There Have Been Some Challenges in Studies, I Remain Optimistic About the Pipeline (RHHBY)
Dec 1, 2025
Mandatory versus optional licensing: India's strategic challenge in ensuring access to medications.
India is navigating the complex balance between intellectual property rights and public health through compulsory licensing (CL) and voluntary licensing (VL) mechanisms. Recent developments, including the Delhi High Court's ruling favoring Natco Pharma's generic version of Roche's Evrysdi, highlight the effectiveness of CL in improving access to medicines. However, concerns arise over the India-UK CETA potentially prioritizing VL, impacting India's ability to utilize TRIPS flexibilities.
Dec 1, 2025
Trump's Prescription: The Convergence of Pharmaceutical Corruption and Trump's Erratic Behavior - CounterPunch.org
A recent article critiques the pharmaceutical industry's reliance on patent monopolies, arguing they inflate drug prices and hinder access to essential medications. The author suggests that upfront funding for research could replace these monopolies, potentially saving consumers over $550 billion annually. The piece highlights the need for a serious debate on drug pricing reform, emphasizing the inefficiencies and corruption fostered by the current system.
Dec 1, 2025
DoP calls for applications under the PLI program for the production of two bulk drugs.
The Department of Pharmaceuticals (DoP) has invited applications under the Production Linked Incentive (PLI) scheme for bulk drugs, aiming to support eight firms in producing key ingredients for the broad-spectrum antibiotic meropenem and the antiretroviral drug ritonavir.
Dec 1, 2025
Young People in Ludhiana Endangering Their Health with Dog and Horse Injections for Rapid Muscle Growth
In Ludhiana, Punjab, young men are dangerously using veterinary injections intended for dogs and horses to achieve rapid muscle gains, risking severe organ damage within two years. This alarming trend highlights the extreme lengths individuals are willing to go in pursuit of fitness, raising serious health concerns.
Dec 1, 2025
The pharmaceutical mergers and acquisitions market is poised for significant expansion.
The Pharma M&A Deals Market is experiencing significant growth, with total deal value reaching USD 152 billion in Q2 2025. Major companies like Pfizer, Johnson & Johnson, and Merck & Co. are acquiring biotech firms to enhance their portfolios in oncology, neurology, and gene therapy. The market is driven by patent expiries and a strong interest in advanced therapies.
Dec 1, 2025
Smuggling of Codeine Cough Syrup Leads to Child Fatalities, Provokes Outrage in Madhya Pradesh Assembly
A crackdown on the illegal trade of Codeine cough syrups in India has revealed a syndicate diverting these prescription drugs for recreational use, leading to child deaths and igniting outrage in the Madhya Pradesh Assembly. The situation highlights the urgent need for stricter regulations to prevent such abuses.
Dec 1, 2025
WHO advocates for universal access to Ozempic-like medications, not limited to the wealthy - Politico.eu
The WHO is urging pharmaceutical companies to adopt tiered pricing and voluntary licensing for GLP-1 drugs, including semaglutide, to enhance access in low-income countries. Key patents for Novo Nordisk's Ozempic and Wegovy will expire soon, allowing generics like Dr. Reddy’s planned semaglutide-based drug to enter the market by 2026, potentially lowering prices.
Dec 1, 2025
A Lack of Regulation in the "Pharmaceutical Orange Book"? Recent collaboration in patent intelligence has a ...
Brazil's Ministry of Health and ABIFINA have signed a patent-intelligence cooperation agreement to enhance patent information use within the Unified Health System (SUS). The agreement, valid for 48 months, aims to improve access to patent data on strategic health products, including biosimilars. This initiative is part of a broader effort to strengthen Brazil's Health Economic-Industrial Complex.
Dec 1, 2025
Pharmaceutical exports expected to see significant growth as original drugs lose patent protection in five years.
Pharmaceutical exports are projected to thrive, with over $250 billion in products set to go off patent by 2030, according to Pharmexcil Vice-Chairman Bhavin Mehta. He noted that exports could rise significantly as generics become available. The US market shows signs of stability, with major companies like Eli Lilly and Pfizer committing to investments. Mehta also highlighted improved quality assurance in cough syrup exports.
Dec 1, 2025
Eli Lilly reduces the cost of its widely-used weight-loss medication, Zepbound - USA Today
Eli Lilly has reduced prices for its weight loss drug Zepbound by $50 to $100 for direct consumers, with the new price for a month's supply ranging from $299 to $449. This move follows similar cuts by rival Novo Nordisk for Wegovy and Ozempic. Both companies are responding to pressure to improve access to obesity medications amid rising costs.
Dec 1, 2025
Recursion's New CEO Discusses Transforming AI-Developed Medications into Clinical Evidence
Recursion has announced a leadership transition, with Najat Khan, PhD, taking over as CEO from Chris Gibson on January 1st. Under Khan's leadership, the company aims to enhance its AI drug discovery platform, focusing on partnerships with Roche and Genentech, while addressing unmet needs in oncology, neuroscience, and rare diseases. Gibson will remain as board chair.
Nov 30, 2025
New Gelatin Hydrogel Created for Simultaneous Delivery of ARV-471 and Palbociclib in Breast Cancer Treatment
Researchers have developed a gelatin-based hydrogel for the dual delivery of ARV-471, an oral selective estrogen receptor degrader, and Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, to enhance breast cancer therapy. This innovative system aims to improve drug efficacy and minimize side effects, showing promising results in preclinical models for combination treatments.
Nov 30, 2025
Market competition, rather than price regulations, has led to a significant reduction in GLP-1 prices - Washington Examiner
Novo Nordisk has announced significant price cuts for its GLP-1 drugs, Ozempic and Wegovy, reducing monthly costs from around $1,000 to as low as $349 for direct purchases. This move aims to regain market share from Eli Lilly, which currently holds 57.9% of the GLP-1 market. The price reductions highlight the benefits of competition over government price controls in the pharmaceutical industry.
Nov 30, 2025
Breaking Boundaries: Intellectual Property in the Era of Needle-free Vaccines - Healthcare - Australia
Advancements in needle-free vaccine delivery systems are transforming immunization practices, enhancing patient access and simplifying distribution. Companies like Vaxxas and PharmaJet are leading innovations with technologies such as microarray patches and jet injectors. The shift towards device-based vaccination is also reshaping patent strategies, emphasizing the importance of protecting delivery mechanisms alongside traditional vaccine formulations.
